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Abstract
Background:  Studies on Plasmodium falciparum gametocyte development and dynamics have
almost exclusively focused on patients treated with antimalarial drugs, while the majority of parasite
carriers in endemic areas are asymptomatic. This study identified factors that influence
gametocytaemia in asymptomatic children in the absence and presence of pyrimethamine-
sulphadoxine (SP) antimalarial treatment.
Methods: A cohort of 526 children (6 months – 16 years) from western Kenya was screened for
asexual parasites and gametocytes and followed weekly up to four weeks. Children with an
estimated parasitaemia of ≥1,000 parasites/µl were treated with SP according to national guidelines.
Factors associated with gametocyte development and persistence were determined in untreated
and SP-treated children with P. falciparum mono-infection.
Results: Gametocyte prevalence at enrolment was 33.8% in children below five years of age and
decreased with age. In the absence of treatment 18.6% of the children developed gametocytaemia
during follow-up; in SP-treated children this proportion was 29.8%. Age, high asexual parasite
density and gametocyte presence at enrolment were predictive factors for gametocytaemia. The
estimated mean duration of gametocytaemia for children below five, children from five to nine and
children ten years and above was 9.4, 7.8 and 4.1 days, respectively.
Conclusion:  This study shows that a large proportion of asymptomatic untreated children
develop gametocytaemia. Gametocytaemia was particularly common in children below five years
who harbor gametocytes for a longer period of time. The age-dependent duration of
gametocytaemia has not been previously shown and could increase the importance of this age
group for the infectious reservoir.
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Background
The transmission of Plasmodium falciparum parasites from
humans to mosquitoes requires the presence of infectious
gametocytes in the human peripheral blood. The preva-
lence of gametocytes is, therefore, commonly used as a
parameter of malaria transmission. Any strategy that inter-
feres with gametocyte development or persistence could
result in a reduction of malaria transmission. For this pur-
pose, it is important to identify parameters that influence
gametocyte development as well as gametocyte dynamics
under natural conditions. Although the majority of para-
site carriers in endemic countries are asymptomatic [1],
studies on gametocyte development and dynamics have
almost exclusively focused on patients treated with anti-
malarial drugs [2-11]. In these studies, gametocytaemia is
influenced by the duration of symptoms [3,7], anaemia
[4,7], type of antimalarial treatment [2,4,5,9], response to
treatment [3,7,10] and age of infected individuals
[6,8,11]. The relation between asexual parasites and
gametocytes remains equivocal; a positive relation has
been described between asexual parasite density at enrol-
ment and gametocyte prevalence after treatment [6], but
this was contradicted by several other studies [2-4].
This study describes the dynamics of gametocytaemia in a
cohort of asymptomatic children naturally exposed to
malaria in western Kenya. Children with microscopically
detectable parasitaemia were observed longitudinally.
Those developing parasitaemia at levels requiring antima-
larial treatment were treated with the first line drug
pyrimethamine-sulphadoxine (SP). This study identified
factors associated with P. falciparum gametocyte produc-
tion in the absence or presence of SP-treatment. Within
the group of gametocyte carriers, factors associated with
gametocyte persistence were determined.
Methods
Study area and design
This five week study was conducted in October – Novem-
ber 2001 in Mbita and Lwanda, small rural villages on the
shores of Lake Victoria in Suba district, western Kenya.
The transmission of P. falciparum is variable depending
upon local environmental conditions that support mos-
quito populations. The entomological inoculation rate
(EIR) was recently estimated at six infectious bites per per-
son per month [12]. Whilst variation in EIR may influence
the clinical spectrum of malaria and gametocytaemia it is
unlikely to be a factor in this short study. Data were col-
lected as described elsewhere [13]. Briefly, apparently
healthy children (aged six months – sixteen years) were
recruited from primary schools and the community.
Screening for asexual parasites and gametocytes of P. falci-
parum took place weekly for a period of five weeks. Finger
prick blood samples were collected and thick blood
smears were dried, stained with 10% Giemsa and exam-
ined microscopically. A slide was considered negative if
no asexual parasites were seen after examination of 100
fields. Gametocyte and asexual parasite densities were
assessed by counting against 500 and 200 leukocytes,
respectively, and converted to numbers of parasites per µl
by assuming a standard leukocyte count of 8,000/µl. Chil-
dren with a positive blood smear with an estimated para-
site density higher than 1,000 parasites/µl on the initial or
any subsequent visits were treated immediately with
pyrimethamine-sulphadoxine (SP) according to national
guidelines. Only children who were treated once in the
first or second week of the study were included in the
analyses to achieve a minimum follow up period of three
weeks. In case of treatment failure, alternative treatment
was administered under supervision of the Clinical
Officer. This resulted in the exclusion from the further
study and follow-up.
Children or guardians signed an informed consent form.
This study was approved by the ethical committee of the
Kenya Medical Research Institute (KEMRI) and by the
National Institute of Health (NIH) ethical review board of
the United States.
Data analyses
Children who presented on at least three consecutive vis-
its were used for analyses. Those who reported the use of
antimalarial drugs in the two weeks prior to enrolment or
had a Plasmodium malariae mixed infection were excluded.
The influence of age on transformed (natural logarithm)
parasite densities was analysed in linear regression mod-
els. Discrete data were compared using chi-square or
Fisher's exact test, trends in binary outcomes using the
Cochran-Armitage test for trend. Predictive factors for
gametocyte prevalence on days seven or fourteen were
tested in non-treated and SP-treated children separately,
using multiple regression models with SAS Generalized
Estimating Equations (GEE). Presentation parasitaemia
was included in the models as a continuous variable and
non-parasitaemic children were excluded from the analy-
ses. A random effect was included in the models to allow
for correlations within individuals. The Kaplan-Meier esti-
mator was used to determine the proportion of parasitae-
mic children developing gametocytaemia during the
follow-up period. Only for this analysis, gametocyte carri-
ers at enrolment were excluded.
The duration of gametocytaemia in gametocyte carriers
was estimated using the method described by Drakeley et
al. [14], assuming that a single gametocyte positive slide
represented gametocytes circulating in the peripheral
blood for at least 2.5 days [15]. When children had game-
tocyte positive blood films on successive weeks, the esti-
mated duration of gametocytaemia was the interval
between observations plus 2.5 days.Malaria Journal 2004, 3 http://www.malariajournal.com/content/3/1/18
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Results
Gametocyte prevalence at enrolment was 33.8% (22/65)
in children below five years of age and was negatively
associated with age (table 1). Mean gametocyte density at
enrolment was 24.5 (IQR 16–32) gametocytes/µl with no
difference between age groups, whilst both asexual para-
site prevalence and density decreased with age. SP treat-
ment was given to 27.2% (143/526) of the children who
presented with asexual parasites on the first or second visit
with a geometric mean density of 1,108.0 (IQR 249–
4235) parasites/µl. A group of 121 parasitaemic children
exhibited relatively low parasitaemia at presentation (geo-
metric mean density of 203.0 (IQR 80–400) parasites/µl)
and was not given treatment throughout the study. The
Kaplan-Meier estimator of time to gametocytaemia for
these two groups of parasitaemic children is presented in
figure 1. At the end of the four week follow-up period, the
cumulative proportion of gametocytaemia was lower in
children not receiving antimalarial treatment than in SP
treated children, 18.6% and 29.8%, respectively. In both
groups, gametocyte prevalence during the first two weeks
of follow-up was independently associated with several
factors (table 2). The risk for gametocytaemia during fol-
low-up was positively associated with asexual parasite
density at enrolment and negatively with age. Children
with detectable gametocytes at enrolment were more
likely to show gametocytes during follow-up, after adjust-
ment for age and asexual parasite density at the start of
treatment. In children who received SP treatment, the
probability of gametocyte prevalence seemed higher on
day seven after treatment compared to day fourteen,
although this was not statistically significant. R1 resist-
ance did not increase risk of gametocytes during follow-
up while R2/R3 resistance did show such an association,
OR 3.40 (95% CI 1.61–7.19). The estimated mean dura-
tion of gametocytaemia was 9.4 days (range 2.5 – 23.5)
for children below five years of age, 7.8 days (range 2.5 –
23.5) for children aged five to nine years and 4.1 days
(range 2.5–16.5) for children aged ten years and above.
The duration of gametocytaemia was negatively associ-
ated with age (β = -1.65, se(β) = 0.73; p = 0.02), after
adjustment for asexual parasite density and gametocyte
density at enrolment. Treatment with SP did not inde-
pendently influence the duration of gametocytaemia.
Discussion
This descriptive study on the largely neglected group of
asymptomatic children was part of a larger study on SP
and gametocytes. A direct comparison between SP-treated
and untreated children was not the aim of the current
study and would require a different study design. SP-
treated and untreated children differed with regards to
treatment and asexual parasite density at enrolment and
were therefore analysed separately.
In this study, 18.6% of the asymptomatic non-treated
children developed gametocytaemia during a four week
follow-up period. Gametocytaemia was particularly com-
mon in children <5 years of age, of whom one-third were
already carrying gametocytes on enrolment. The high
gametocyte prevalence in young children is in line with
previous findings [6,11], although the longer duration of
gametocytaemia for this age group has not been reported
before. The age dependent duration of gametocytaemia
could not be explained by asexual parasitaemia, gameto-
cyte density or SP treatment, suggesting a role for age-
dependent immune suppression of gametocytaemia.
Acquired sexual stage specific immunity has previously
been reported to influence gametocyte prevalence [16],
but remains poorly defined. Although the exact duration
of gametocytaemia could not be determined because of
weekly intervals in data-collection, the longer estimated
duration of gametocytaemia in the youngest age group
combined with their higher gametocyte prevalence could
increase the importance of this age group for the infec-
tious reservoir in this area. The importance of children as
the infectious reservoir has been stressed elsewhere [17].
Differences in gametocytaemia during follow up should
Table 1: Parasitological data at enrolment
Age N Asexual parasite 
prevalence, % (n)¥
Asexual parasite density, 
mean (IQR)†
Gametocyte prevalence 
% (n)¶
Gametocyte density 
mean (IQR)‡
<5 years 65 73.8 (48) 2302.4 (530–14149) 33.8 (22) 25.3 (16–32)
5–9 years 211 50.2 (106) 357.8 (120–1040) 10.4 (22) 27.9 (16–32)
10–16 years 250 30.4 (76) 202.7 (80–440) 5.2 (13) 18.8 (16–23)
Total 526 43.7 (230) 444.8 (120–1220) 10.8 (57) 24.5 (16–32)
IQR = interquartile range ¥ Cochran-Armitage test for age-dependent trend in prevalence of asexual parasites (Z = -6.75, P < 0.001). † Geometric 
mean of parasite carriers only (parasites/µl). Linear regression for log-transformed asexual parasite density and age groups, β = -1.155; se(β) = 
0.147, P < 0.001. ¶ Cochran-Armitage test for age-dependent trend in prevalence of gametocytes (Z = -5.91, P < 0.001). ‡ Geometric mean of 
gametocyte carriers only (parasites/µl). Linear regression for log-transformed gametocyte density and age groups, β = -0.123; se(β) = 0.166, P = 
0.46.Malaria Journal 2004, 3 http://www.malariajournal.com/content/3/1/18
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be interpreted carefully since they are at least partially
explained by differences in asexual parasite density at
enrolment. The observed peak in gametocytaemia on day
seven after SP treatment has been previously described [3-
6] and may include gametocytes circulating prior to treat-
ment since seven days may be short for gametocytogene-
sis, as was suggested by in vitro observations [18]. This
study determined predictive factors for gametocytaemia
for SP-treated and untreated children independently and
found that risk factors were similar in both groups. Fur-
The cumulative proportion of gametocytaemia in SP-treated and untreated children Figure 1
The cumulative proportion of gametocytaemia in SP-treated and untreated children. Kaplan-Meier estimator of 
the time to gametocytaemia for untreated children (dotted line) and SP-treated children (solid line). Groups differed in asexual 
parasite density at enrolment. Patients with incomplete follow-up are marked on the curve. Gametocyte carriers on day 0 
were excluded, as well as children who reported the use of antimalarial drugs prior to enrolment. Log-rank P = 0.05Malaria Journal 2004, 3 http://www.malariajournal.com/content/3/1/18
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thermore, age and gametocyte presence at enrolment were
previously described as predictors for gametocytaemia in
symptomatic treated children [4,6-8,11]. Asexual parasi-
taemia at enrolment was positively associated with game-
tocytaemia during follow-up. Other studies [2-4] may not
have found such an association because they only
included patients with a high parasitaemia, resulting in
little variation in asexual parasite density. Parasitological
treatment failure was an important predictor of gametocy-
taemia in the SP-treated group [13].
Conclusions
This study shows that many asymptomatic children
develop gametocytes, even in the absence of treatment.
Gametocyte prevalence is especially high in children
below five years of age who also appear to harbor gameto-
cytes for a longer period of time. Risk factors for gameto-
cytaemia are similar to those described in symptomatic
children and do not appear to differ between treated and
untreated children.
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